MA-PRECISELY
8.12.2022 15:01:43 CET | Business Wire | Press release
Precisely, the global leader in data integrity, in collaboration with SAPinsider, today announced the results of new global research that highlights the importance of process automation in building robust supply chains. Findings from the new benchmark report, Process Automation in Supply Chain, show that 51% of respondents cite resiliency as the top supply chain concern driving the need for process automation, with agility close behind at 46%. A backdrop of disruptive world events means businesses are increasingly battling against global supply chain disruption, as well as mounting pressures to keep pace with changing consumer preferences for digital, local, and sustainable goods – resulting in an urgent need for supply chain transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005434/en/
51% of business leaders cite resiliency as top supply chain concern driving need for process automation (Graphic: Business Wire)
The research found that 89% of respondents believe process automation in the supply chain is either “important” or “very important” to attain digital transformation objectives. However, a major gap remains between where the industry needs to be and where it currently stands: Nearly three-fourths (72%) indicated that less than 50% of their supply chain processes are currently automated, with this dropping to just 25% for a further one-third of the respondents.
“With recent world events including the COVID-19 pandemic, the war in Ukraine, and impacts from climate change, it’s no surprise that supply chain resiliency is top of mind for businesses worldwide,” said Mark Vigoroso, Chief Content Officer at SAPinsider. “While adoption of technologies has been slow to-date, the need to create a resilient supply chain ecosystem has never been more apparent, and we’re seeing organizations increasingly turn to process automation as a way to build robust supply chain capabilities and help navigate the uncertainty in the market.”
“These new findings from SAPinsider highlight the importance of automation when it comes to complex, data intensive, SAP processes, such as for supply chain,” said John Reda, SVP – Product Management for Data Integration at Precisely. “The Precisely Automate Evolve platform, formerly Winshuttle Evolve, helps customers to gain agility and speed by simplifying and streamlining processes. The flexible, scalable nature of the platform helps create and maintain resilient supply chains - delivering increased efficiency, visibility and governance that improve results and reduce the risks inherent in today’s unpredictable business environment.”
The research additionally shows that the key objectives for deploying process automation have become more strategic over time, and include the realization of benefits such as:
- End-to-end process visibility (82%)
- Increased process efficiency (79%)
- Defining and documenting standardization (77%)
- Integrated processes across end-to-end supply chain (75%)
- Building internal skillset (72%)
It also uncovers an increased appetite to explore more advanced automation technologies as businesses plan for 2023 and beyond -- with nearly half of all respondents (47%) stating intelligent automation, such as AI and machine learning, is a key capability they are considering implementing over the next 24 months.
“Ultimately, supply chain resilience relies upon a programmatic approach for improving end-to-end process visibility and risk monitoring. To be successful, supply chains must become both digital and autonomous to keep pace with disruptive global events and changing consumer expectations,” continued Reda. “It’s clear that process automation is critical, but the success of digitized processes and workflows will also rely upon the accuracy, consistency and context of the data feeding them. Supply chain transformation, fueled by data integrity, will be the key to confident decision-making during the uncertain times ahead.”
Read the full SAPinsider Benchmark Report Process Automation in Supply Chain here or for further insights on the role of process automation in building robust supply chains, view our on-demand webinar “Process Automation Trends in SAP Supply Chain for 2023” here.
About SAPinsider and Survey Methodology
SAPinsider comprises the largest and fastest growing SAP membership group worldwide, with more than 500,000 members across 205 countries. The Supply Chain Research Report, conducted in partnership with Precisely, surveyed SAP Insider members between July and September 2022 to gauge the use and future investment of process automation in supply chain. The survey was administered to 105 members of the SAPinsider Community and generated responses from across a wide range of geographies, industries, and company sizes.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
